GTCM
ITCI

Gyon Technologies Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Gyon Technologies Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-9,242
Closed -$314K – 513
2021
Q1 		$314K Sell
9,242
-33,539
-78% -$1.16M 0.14% 262
2020
Q4 		$1.36M Buy
+42,781
New +$1.12M 0.47% 59

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Gyon Technologies Capital Management's ITCI Position: Q2 2021 in Review

Gyon Technologies Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2021, closing a stake of 9,242 shares — an estimated $314K sold.

Gyon Technologies Capital Management first reported a position in ITCI in Q4 2020 and held it in 2 quarters. The position peaked at $1.36M in Q4 2020. 187 funds tracked by Wall St. Rank hold ITCI as of Q2 2021.

  • Gyon Technologies Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2021 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 9,242 Intra-Cellular Therapies Inc. shares in Q2 2021, an estimated $314K.
  • Gyon Technologies Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2020 and held it in 2 quarters.
  • Gyon Technologies Capital Management's Intra-Cellular Therapies Inc. position peaked at $1.36M in Q4 2020.
  • 187 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2021.

Based on Gyon Technologies Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.